Hybridoma Technology: The Preferred Method for Monoclonal Antibody Generation for
            <i>in vivo</i>
            Applications

Zaroff, Samantha; Tan, Guan Huat

doi:10.2144/btn-2019-0054

Cited by 37 publications

(31 citation statements)

References 20 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to generate an antibody, purified protein is required and this protein needs to be immunogenic in order to generate an immune response once the protein is injected into an animal host [30]. Following the time required to initiate an immune response and generate antibodies, the B-cells of the spleen are removed and fused with myeloma cells to form hybridomas which are then tested to identify the ones which produce the best monoclonal antibodies for their target [55]. This process has limitations, as you need to know what your target, or protein, is to begin with.…”

Section: Towards a Better System Of Detecting Proteome Signaturesmentioning

confidence: 99%

Antibodies, Nanobodies, or Aptamers—Which Is Best for Deciphering the Proteomes of Non-Model Species?

Dhar

Samarasinghe

Shigdar

2020

IJMS

View full text Add to dashboard Cite

This planet is home to countless species, some more well-known than the others. While we have developed many techniques to be able to interrogate some of the “omics”, proteomics is becoming recognized as a very important part of the puzzle, given how important the protein is as a functional part of the cell. Within human health, the proteome is fairly well-established, with numerous reagents being available to decipher cellular pathways. Recent research advancements have assisted in characterizing the proteomes of some model (non-human) species, however, in many other species, we are only just touching the surface. This review considers three main reagent classes—antibodies, aptamers, and nanobodies—as a means of continuing to investigate the proteomes of non-model species without the complications of understanding the full protein signature of a species. Considerations of ease of production, potential applications, and the necessity for producing a new reagent depending on homology are presented.

show abstract

Section: Towards a Better System Of Detecting Proteome Signaturesmentioning

confidence: 99%

Antibodies, Nanobodies, or Aptamers—Which Is Best for Deciphering the Proteomes of Non-Model Species?

Dhar

Samarasinghe

Shigdar

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Antibody-based biologics are one of the best-selling classes of biomolecules in today's market. Advancement in mAb generation technologies in recent years has made ease in identification of new target antigens to be explored in diagnostic and therapeutic approaches [18,19]. Several mAb generation technologies had been developed over the years, to isolate mAbs from immune and non-immune sources using hybridoma, display methods, and more advanced novel mAb development technologies like single B cell amplification and culturing methods.…”

Section: Introductionmentioning

confidence: 99%

“…Hybridoma technology is the primitive, most fundamental and successful methodology in the field of mAb isolation [19]. This technology is quite robust and useful in discovering thousands of antibodies for different applications [22].…”

Section: Introductionmentioning

confidence: 99%

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Parray

Shukla

Samal

et al. 2020

International Immunopharmacology

124

111

View full text Add to dashboard Cite

The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ III clinical trials targeting new unique targets. To date, approximately more than 80 monoclonal antibodies (mAbs) have been approved. A total of 7 novel antibody therapeutics had been granted the first approval either in the United States or European Union in the year 2019, representing approximately 20% of the total number of approved drugs. Most of these licenced mAbs or their derivatives are either of hybridoma origin or their improvised engineered versions. Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. The recent advent of antibody engineering technology has superseded the species level barriers and has shown success in isolation of hybridoma across phylogenetically distinct species. This has led to the isolation of monoclonal antibodies against human targets that are conserved and non-immunogenic in the rodent. In this review, we have discussed in detail about hybridoma technology, its expansion towards different animal species, the importance of antibodies isolated from different animal sources that are useful in biological applications, advantages, and limitations. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs.

show abstract

“…Approximately a hundred years have passed since Paul Ehrlich proposed the concept of antibodies as the "magic bullet" for selective targeting of malignant cells. 1 More recently, progress in hybridoma technologies and recombinant DNA techniques has enabled the generation of highly effective monoclonal antibodies (mAbs) [2][3][4][5][6][7][8] to be developed for therapeutic purposes. However, in spite of the conceptual simplicity of antibody-drug conjugates (ADCs) as a therapeutic modality, the design, generation, and clinical use of these therapies have proved challenging.…”

Section: Introductionmentioning

confidence: 99%

Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

2020

View full text Add to dashboard Cite

Hybridoma Technology: The Preferred Method for Monoclonal Antibody Generation for in vivo Applications

Cited by 37 publications

References 20 publications

Antibodies, Nanobodies, or Aptamers—Which Is Best for Deciphering the Proteomes of Non-Model Species?

Antibodies, Nanobodies, or Aptamers—Which Is Best for Deciphering the Proteomes of Non-Model Species?

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

Contact Info

Product

Resources

About